EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Penn State Cancer Institute, Dana-Farber Cancer Institute, Loyola University Chicago, Harvard University, Massachusetts General Hospital, Pennsylvania State University, University of Pennsylvania, Jesse Brown VA Medical Center, Oregon Health & Science University, Georgetown University, Thomas Jefferson University, Sidney Kimmel Cancer Center, Johns Hopkins University, Johns Hopkins Medicine
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4213009572